Cytomx Therapeutics, Inc. · NASDAQ:CTMX

Cytomx Therapeutics — 40th Annual J.P. Morgan Healthcare Conference (January 2022)

30 slides from Cytomx Therapeutics's conference presentation, Jan 10, 2022

  1. Slide 1: 40th Annual J.P. Morgan Healthcare Conference

    © 2022 CytomX Therapeutics, Inc. 40 th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman January 12, 2022

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements This presentation may contain projections and other forward - looking statements regarding future events. All statements other tha n statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology p

  3. Slide 3: Destroying Cancer. Differently.

    © 2022 CytomX Therapeutics, Inc. Destroying Cancer. Differently.

  4. Slide 4: Multi-Modality Platform for Conditional Activation and Tissue Localization

    CD3 EGFR CytomX has Pioneered a Multi - Modality Platform for Conditional Activation and Tissue Localization of Potent Biologic Drug Candidates Cytokines Antibodies Antibody - Drug Conjugates T - cell Bispecifics Our Value Proposition The Leading Paradigm of Biologics Localization, Opening Unparalle

  5. Slide 5: The Probody Therapeutic Platform – Exploiting Cancer's Achilles' Heel

    The Probody ® Therapeutic Platform – Exploiting Cancer’s Achilles’ Heel 5 More Binding in Tumors Less Binding in Normal Tissues Protease Mask Substrate linker Protease T arget PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are th

  6. Slide 6: Integrated Business Model for Long-Term Value Creation

    Integrated Business Model for Long - Term Value Creation 6 • 4 global partnerships • 3 partnered programs in clinic • Raised >$500M non - dilutive capital to date • Robust & diverse portfolio • 6 INDs • 4 Phase 2 assets in 9 cancer types • Leader in conditional activation • Tunable platform • Multi

  7. Slide 7: Experienced Leadership Team

    Experienced Leadership Team 7 Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman >20 years of experience in biotech with roles in R&D, business development, financing and general management Amy C. Peterson, M.D. EVP, Chief Development Officer >15 years of leadership experienc

  8. Slide 8: Strong Track Record of Execution Towards Our Vision

    Strong Track Record of Execution Towards Our Vision Becoming a Sustainable, Commercial Stage Oncology Leader 8 Financials Clinical Alliance $125M public equity offering 2014 2016 2017 2018 2019 2020 2008 2021 2015 2022 CX - 2009 Ph1 data at AACR CX - 904 IND $80M upfront $100M public equity offering

  9. Slide 9: CytomX Leadership has Established Conditional Activation as a Strategic Area

    CytomX Leadership has Established Conditional Activation as a Highly Strategic Area of Biologics Research and Development 9 2016 2019 2020 2015 2021 2022 Public Companies Recent M&A

  10. Slide 10: Leading Platform, Deepest Pipeline, Broadest Clinical Experience

    Modality Product Candidate Target - Payload Indication Preclinical Phase 1 Phase 2 Commercial Rights Antibody - Drug Conjugate Praluzatamab ravtansine (CX - 2009) CD166 - DM4 HR+/HER2 - non - amp BC TNBC CX - 2029 CD71 - MMAE Squamous NSCLC HNSCC Esophageal/GEJ DLBCL CX - 2043 EpCAM - DM21 Solid tum

  11. Slide 11: Praluzatamab Ravtansine (CX-2009) First-in-Class ADC

    Praluzatamab Ravtansine (CX - 2009) First - in - Class Antibody - Drug Conjugate (ADC) Directed Toward CD166 for HER2 - non - Amplified Advanced Breast Cancer DM4 PAYLOAD

  12. Slide 12: CD166 is a Novel ADC Target with High Tumor Expression

    CD166 Expression (H - Score) in Breast Cancer Patients CD166 is a Novel ADC Target with High Tumor Expression Undruggable Using Conventional ADC Because of High Expression on Normal Tissue 12 log 2 normalized expression High Expression on Tumors High CD166 Expression by IHC Source: Lui J. et al SABC

  13. Slide 13: Praluzatamab Ravtansine Demonstrated Meaningful Clinical Benefit in Phase 1

    Praluzatamab Ravtansine Demonstrated Meaningful Clinical Benefit in Breast Cancer in Phase 1 13 Heavily pretreated patients with measurable disease who received ≥ 4 mg/kg CX - 2009 Source: Lui J. et al SABCS 2020; PS 11 - 07 CBR= clinical benefit rate (CR, PR or SD for 16 or 24 wks ); cPR = confirme

  14. Slide 14: Ongoing Multi-Arm Breast Cancer Phase 2 Study

    Ongoing Multi - Arm Breast Cancer Phase 2 Study Initial Data Readout Expected in 2022 14 Ocular prophylaxis required HR+/HER2 non - amplified • 0 – 2 prior cytotoxics for advanced disease • Measurable disease required • No active corneal disease TNBC • CD166 High • ≥ 1 and ≤ 3 priors for advanced di

  15. Slide 15: Broad Potential in HR+/HER2- Treatment Paradigm

    PARPi (Olaparib, Talazoparib ) +/ - Hormone therapy, Praluzatamab Ravtansine Has Broad Potential in Current HR+/HER2‒ Treatment Paradigm 15 First Line (82K patients) Hormone Therapy Eligible (2021 US and EU5 patients) Chemotherapy Eligible (2021 US and EU5 patients) Second Line ( 53K patients) Chemo

  16. Slide 16: Broad Potential in Current TNBC Treatment Paradigm

    Praluzatamab Ravtansine Has Broad Potential in Current TNBC Treatment Paradigm 16 First Line (17K patients) Second Line (12K patients) Third Line (8K patients) Chemotherapy Sources: NCCN Breast Cancer Guidelines, 2021; DRG Breast Cancer Treatment 2021; DRG Breast Cancer Epidemiology 2021; CytomX a n

  17. Slide 17: CX-2029 First-in-Class ADC Directed Toward CD71

    CX - 2029 First - in - Class Antibody - Drug Conjugate (ADC) Directed Toward CD71 (Transferrin Receptor) for Multiple Cancer Types MMAE PAYLOAD

  18. Slide 18: CD71 is a High Potential ADC Target With High Tumor Expression

    CD71 is a High Potential ADC Target With High Tumor Expression • Undruggable target with conventional ADC due to central role in iron metabolism • CX - 2029 is a CD71 - directed MMAE conjugated conditionally activated ADC • Anti - cancer agent with first - in - class potential HNSCC LYMPHOMA ESOPHAG

  19. Slide 19: CX-2029 Phase 1 Clinical Activity in Squamous Cancers

    CX - 2029 Phase 1 Clinical Activity in Squamous Cancers 19 sqNSCLC or HNSCC patients with measurable disease who received ≥ 2 mg/kg CX - 2029 Percent Change in Tumor Burden from Baseline (%) Weeks Since Treatment Initiation 2 mg/kg 3 mg/kg 5 mg/kg Dose Level: SD PR Response: PD HNSCC HNSCC HNSCC sqN

  20. Slide 20: Ongoing Multi-Cohort CX-2029 Phase 2 Expansion Study

    Ongoing Multi - Cohort CX - 2029 Phase 2 Expansion Study 20 sqNSCLC, HNSCC and esophageal/GEJ • Prior platinum and checkpoint inhibitor required • Documented progression after at least one prior systemic regimen for advanced disease DLBCL • ≥2 prior regimens (including anti - CD20 based therapy); no

  21. Slide 21: No Current Standard-of-Care in 3L+ Post-Checkpoint Inhibitor Setting

    No Current Standard - of - Care in 3L+ Post - Checkpoint Inhibitor Setting CX - 2029 Interim Phase 2 ORR of 18.8% in 3L+ SqNSCLC Enrollment Continues 21 Interim Takeaways from Ongoing Phase 2 Expansion Study • Heavily - pretreated and unselected sqNSCLC patients (n=16*) ‒ Medium # prior therapies =

  22. Slide 22: Emerging Opportunity for CX-2029 in 3L+ SqNSCLC

    Emerging Opportunity for CX - 2029 in 3L+ SqNSCLC 22 Sources: NCCN NSCLC Guidelines, 2021; DRG NSCLC Treatment 2021; DRG Breast Cancer Epidemiology 2021; CytomX analysis First Line (81K patients) Second Line (49K patients) Third Line (20K patients) Chemotherapy Nivolumab + ipilimumab +/ - chemothera

  23. Slide 23: Conditionally Activated EGFR x CD3 T-Cell-Engaging Bispecific Antibody

    EGFR CX - 904 Conditionally Activated EGFR x CD3 T - Cell - Engaging Bispecific Antibody (TCB) CD3

  24. Slide 24: Conditionally Activated TCBs Open Target Landscape for Solid Tumors

    Conditionally Activated TCBs Open Target Landscape for Solid Tumors 24 Normal Tissue Source: Image adapted from Middelburg et al. Cancers. 2021 Conventional TCB Conditionally Activated TCB CD3+ T cell • Conventional TCBs are highly potent, however toxicity is a challenge due to high EGFR expression

  25. Slide 25: EGFR: A High Potential Target for Conditionally Activated TCB Modality

    EGFR: A High Potential Target for Conditionally Activated TCB Modality • Epidermal Growth Factor Receptor (EGFR) – EGFR is a tyrosine kinase receptor involved in homeostatic regulation of normal cells and carcinogenesis of epithelial malignacies 1,2 – EGFR plays a crucial role in cancer, and is one

  26. Slide 26: Conditionally Activated EGFRxCD3 TCB Induces Tumor Regressions in Preclinical Studies

    Conditionally Activated EGFRxCD3 TCB Induces Tumor Regressions and Increases MTD in Preclinical Studies 26 * Act - TCB: Protease activated, unmasked TCB; Pb - TCB: Conditionally activated, masked TCB Increases MTD Extends PK Single Agent Efficacy in Human PBMCs engrafted into HCT116 and HT29 Tumor -

  27. Slide 27: Summary and Milestones

    : = ax ee S| @ Summary and Milestones =

  28. Slide 28: Leading Platform, Deepest Pipeline, Broadest Clinical Experience

    Modality Product Candidate Target - Payload Indication Preclinical Phase 1 Phase 2 Commercial Rights Antibody - Drug Conjugate Praluzatamab ravtansine (CX - 2009) CD166 - DM4 HR+/HER2 - non - amp BC TNBC CX - 2029 CD71 - MMAE Squamous NSCLC HNSCC Esophageal/GEJ DLBCL CX - 2043 EpCAM - DM21 Solid tum

  29. Slide 29: Continued Leadership and Execution in 2022

    Continued Leadership and Execution in 2022 29 • Initial CX - 2009 Phase 2 data in breast cancer (Arms A & B) • Expansion phase completion for CX - 2029 and new data updates • CX - 904 Phase 1 study initiation • Early - stage pipeline progress including cytokine program 2022 Outlook

  30. Slide 30: Questions and Answers

    © 2022 CytomX Therapeutics, Inc. Questions and Answers 30

CytomX Therapeutics — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix